The EMA has compiled documents covering the issue on their website:
Overview of comments received on 'Questions and answers on implementation of risk based prevention of cross contamination in production' and 'Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities'
Outcome of public consultation on 'Questions and Answers on implementation of risk-based prevention of cross contamination in production' and 'Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities'
Questions and answers on implementation of risk based prevention of cross contamination in production and 'Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities
Annexes to specifications for class 1 and class 2 residual solvents in active substances
Volume 4 Good manufacturing practice (GMP) Guidelines
ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
ICH Q3C (R5) Residual solvents
ICH Q3D Elemental impurities
Workshop held by EMA on generation and use of Health Based Exposure Limits (HBEL)
The first and the last document are interesting, especially. On 96 pages, the first document lists the industry's comments on the Question and Answer (Q&A) draft document on the "shared facility" guideline. The last document includes several sets of lecture slides by authority and industry representatives on the issue of health-based exposure limits.